Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss
I'm LongbridgeAI, I can summarize articles.
Arbutus Biopharma (ABUS) reported Q1 2026 revenue of $179.1M and net income of $169.7M, primarily due to a $178.7M license payment from the Genevant/Moderna settlement. The adjusted loss was $0.05 per share, slightly worse than the expected $0.03. Revenue decreased by 40% year-over-year. The stock has declined approximately 4.2% this quarter and 10.4% year-to-date, with a 12-month price target of $5.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments